The 2013 EULAR draft guidelines for the treatment of RA include 3 overarching principles and 14 recommendations, the main points of which are as follows: 1. DMARD therapy should be initiated as early as possible after the diagnosis of RA. 2. The goal of treatment is to alleviate the disease or reduce disease activity. 3. Frequent monitoring should be performed, and the treatment regimen should be adjusted if remission is not achieved after up to 3 months of treatment, or if the treatment goal is not achieved after up to 6 months of treatment. Yu@Hua, Department of Rheumatology and Immunology, Fujian Provincial People’s Hospital 4. The first-line treatment strategy should include methotrexate. 5.When patients have contraindications to methotrexate or cannot tolerate it, they can consider including salazosulfapyridine or leflunomide into the treatment regimen. 6. Early treatment with a traditional synthetic DMARD combination is a reasonable alternative to initial methotrexate monotherapy. 7. Consider adding a low-dose glucocorticoid as part of the initial treatment for up to 6 months; the dose should be reduced as quickly as clinically feasible. If treatment goals are not met, consider switching to another synthetic DMARD regimen; if the patient has poor prognostic features, consider adding a biologic DMARD. If the patient does not respond adequately to conventional synthetic DMARD therapy (with or without concurrent glucocorticoid therapy), add a biologic DMARD to methotrexate therapy, which may be be a TNF inhibitor, abciximab or tolimumab. Patients with inadequate response to a biologic DMARD should be switched to another biologic DMARD. patients who fail the first TNF inhibitor therapy may be switched to another TNF inhibitor. 11, For patients who have failed biologic DMARD therapy, Tofacitinib treatment may be considered. 12. For patients in sustained remission, the dosage of corticosteroids should be reduced first. If remission is maintained, curtailment of biologic DMARD therapy may be considered, especially if the patient is also on at least one synthetic DMARD. For patients in durable, long-term remission, a reduction in the dose of traditional synthetic DMARD may be discussed with the physician. 14. Structural damage progression, comorbidities, safety, and disease activity should be taken into account when adjusting therapy.